|
WO2021069602A1
|
|
Variants of gala reductase and their uses
|
|
WO2021053234A1
|
|
Compounds and compositions for treating kidney disease
|
|
WO2021032681A1
|
|
Bone marrow derived cell bone graft material
|
|
WO2021032688A1
|
|
Mesenchymal stromal cell bone graft material
|
|
WO2020120102A1
|
|
Attachment for an immersion objective
|
|
EP3696281A1
|
|
Arginase as biomarker and drug target for pcos
|
|
WO2018228961A1
|
|
Genetic tools and procedure for the phenotypic identification of the genotype of transgenic diploid organisms
|
|
WO2018202837A1
|
|
Method for preparing a cross-linked hydrogel nanomembrane, the cross-linked hydrogel nanomembrane, tem grid comprising the same and use thereof
|
|
US2020032350A1
|
|
Companion diagnostics for leukemia treatment
|
|
AU2017385611A1
|
|
Method for generating higher order genome editing libraries
|
|
WO2018215070A1
|
|
Dual modulators of farnesoid x receptor and soluble epoxide hydrolase
|
|
EP3463470A1
|
|
Treatment and diagnosis of non-proliferative diabetic retinopathy
|
|
EP3414323A1
|
|
Artificial non-ribosomal peptide synthases and their use
|
|
EP3299460A1
|
|
Novel compounds and methods for modulating ubiquitination
|
|
JP2012162540A
|
|
Multivalent chelator for modifying and organizing of target molecule
|
